I’ve been reflecting on hope lately, particularly through the lens of my encounters with IVF patients. It’s a subject that’s not just close to my heart but is also deeply woven into the fabric of what I do every day. Hope, as I’ve seen it, is not simply a desire for a positive outcome; it’s a multifaceted, often paradoxical force that can drive us, blind us, and, at times, exploit us. Working with IVF patients has taught me more about the true nature of hope than any business school could ever impart.
Consider the sheer grit it takes to undergo IVF. The odds are stark: only about 24% of cycles result in live births, and yet, the hope that this cycle, this chance, could be the one keeps patients moving forward. I’ve met couples who’ve been through multiple cycles, each time pinning their hopes on a new set of interventions or add-ons, many of which lack robust evidence supporting their efficacy. It’s a cycle of optimism, disappointment, and perseverance that reveals the complex dance between hope and vulnerability.
When I see a patient who has been through the wringer, emotionally and financially, yet still clings to that sliver of possibility, I realize that hope is a double-edged sword. On one hand, it propels them forward; on the other, it makes them susceptible to exploitation. The commercial side of ART (Assisted Reproductive Technologies) is rife with add-ons marketed as the next big solution—endometrial scratching, assisted hatching, and sperm sorting, to name a few. Yet, the evidence supporting these procedures often remains tenuous at best.
The problem is not just the lack of evidence. It’s the way hope is leveraged to sell these interventions. In my practice, I’ve always believed in being transparent about costs and outcomes. It’s crucial to have these conversations because, without them, we’re doing a disservice to the very people we aim to help. The vulnerability of IVF patients is not just a clinical issue; it’s an ethical one. The hope for a child is so deep-seated and profound that it can cloud judgment, leading to decisions that might not align with the best evidence or even the patient’s best interests.
This brings me to another observation: the parallels between IVF patients and startup founders. Both groups are fueled by hope—hope that their vision will become a reality, hope that their hard work will pay off. But just as in IVF, this hope can lead to risky decisions. In the startup world, I’ve seen founders chase after the latest trends or pivot based on flimsy data, much like IVF patients might opt for the newest add-on. The key in both scenarios is managing expectations and being grounded in reality, something I’ve written about in “What Indian Startups Can Learn from IVF Patients About Managing Expectations”.
What I’ve learned from my patients is that hope needs scaffolding. It needs to be supported by evidence, by honest communication, and by a willingness to accept that not every cycle—or business venture—will succeed. This is where the role of the provider, whether in medicine or investment, becomes crucial. We are not just facilitators of dreams but also the custodians of realistic expectations.
This is not to say that hope should be dampened. Far from it. Hope is what sustains us through adversity. But it needs to be tempered with caution and informed by facts. In the realm of IVF, this means being upfront about the limitations and potential outcomes, something I’ve always emphasized in my practice. Transparency is not just about being honest; it’s about empowering patients to make decisions that are right for them, free from the exaggerated promises of add-ons.
To truly understand hope, one must recognize its capacity to inspire and its potential to mislead. My journey with IVF patients has been a testament to the resilience and strength that hope can foster, but also a reminder of the ethical responsibilities we bear as providers. In both medicine and investing, the lesson is clear: hope is a powerful force, but it must be handled with care.
As I reflect on these experiences, I’m reminded of a patient who once told me, “Hope keeps me going, but it’s also what makes this so hard.” This duality is at the heart of what I’ve learned about hope. It’s a lesson that extends beyond the clinic, offering insights into the nature of human aspiration and the delicate balance we must maintain to ensure that hope remains a source of strength, not a pathway to exploitation.
In closing, I urge my fellow clinicians and investors to consider the role hope plays in their interactions. Are we nurturing it responsibly, or are we allowing it to be a tool for commercial gain? This is a question that demands our attention, for the stakes are high, and the consequences, both emotional and financial, are profound.